{"entity":{"type":"insider","cik":"0001821294","url":"/insider/0001821294","json_url":"/insider/0001821294.json","name":"Eckelman Living Trust Dated February 5, 2014","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":32,"n_filings":12,"first":"2021-02-18","last":"2023-03-02","span_basis":"filed_date"},"name_variants":[{"name":"Eckelman Living Trust Dated February 5, 2014","source":"filing","n_filings":12,"first_seen":"2021-02-18","last_seen":"2023-03-02"}],"transactions":[{"id":8489514,"accession":"0001739614-23-000016","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001739614-23-000016","line_url":"/filing/0001739614-23-000016","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Brendan P.; Eckelman Living Trust Dated February 5, 2014","owner_display_name":"Eckelman Brendan P.","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":24.205768,"price_display":"24.21","price_state":"stated","total_value":968230.72,"total_display":"968,230.72","total_whole":"968,231","shares_owned_after":2035953.0,"shares_owned_after_display":"2,035,953","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-02","scope":"insider","n_lines":2},{"id":8049475,"accession":"0001739614-23-000012","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001739614-23-000012","line_url":"/filing/0001739614-23-000012","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Brendan P.; Eckelman Living Trust Dated February 5, 2014","owner_display_name":"Eckelman Brendan P.","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11250.0,"shares_display":"11,250","price_per_share":25.453737866666668,"price_display":"25.45","price_state":"stated","total_value":286354.551,"total_display":"286,354.55","total_whole":"286,355","shares_owned_after":2076683.0,"shares_owned_after_display":"2,076,683","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-02","filed_date":"2023-02-02","scope":"insider","n_lines":2},{"id":8049469,"accession":"0001739614-23-000012","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001739614-23-000012","line_url":"/filing/0001739614-23-000012","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Brendan P.; Eckelman Living Trust Dated February 5, 2014","owner_display_name":"Eckelman Brendan P.","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":28750.0,"shares_display":"28,750","price_per_share":24.725413704347826,"price_display":"24.73","price_state":"stated","total_value":710855.644,"total_display":"710,855.64","total_whole":"710,856","shares_owned_after":2087496.0,"shares_owned_after_display":"2,087,496","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-02-01","filed_date":"2023-02-02","scope":"insider","n_lines":3},{"id":7852072,"accession":"0001739614-23-000006","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001739614-23-000006","line_url":"/filing/0001739614-23-000006","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Brendan P.; Eckelman Living Trust Dated February 5, 2014","owner_display_name":"Eckelman Brendan P.","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7105.0,"shares_display":"7,105","price_per_share":23.480451133004927,"price_display":"23.48","price_state":"stated","total_value":166828.6053,"total_display":"166,828.61","total_whole":"166,829","shares_owned_after":2118556.0,"shares_owned_after_display":"2,118,556","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-04","filed_date":"2023-01-04","scope":"insider","n_lines":2},{"id":7852067,"accession":"0001739614-23-000006","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001739614-23-000006","line_url":"/filing/0001739614-23-000006","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Brendan P.; Eckelman Living Trust Dated February 5, 2014","owner_display_name":"Eckelman Brendan P.","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":32895.0,"shares_display":"32,895","price_per_share":23.7656096002432,"price_display":"23.77","price_state":"stated","total_value":781769.7278,"total_display":"781,769.73","total_whole":"781,770","shares_owned_after":2133340.0,"shares_owned_after_display":"2,133,340","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-01-03","filed_date":"2023-01-04","scope":"insider","n_lines":3},{"id":6689011,"accession":"0001739614-22-000128","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001739614-22-000128","line_url":"/filing/0001739614-22-000128","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Brendan P.; Eckelman Living Trust Dated February 5, 2014","owner_display_name":"Eckelman Brendan P.","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":27.21706882,"price_display":"27.22","price_state":"stated","total_value":1088682.7528,"total_display":"1,088,682.75","total_whole":"1,088,683","shares_owned_after":2174626.0,"shares_owned_after_display":"2,174,626","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-06","filed_date":"2022-12-07","scope":"insider","n_lines":3},{"id":6642314,"accession":"0001739614-22-000114","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001739614-22-000114","line_url":"/filing/0001739614-22-000114","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Brendan P.; Eckelman Living Trust Dated February 5, 2014","owner_display_name":"Eckelman Brendan P.","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":33.509676605,"price_display":"33.51","price_state":"stated","total_value":1340387.0642,"total_display":"1,340,387.06","total_whole":"1,340,387","shares_owned_after":2207902.0,"shares_owned_after_display":"2,207,902","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-01","filed_date":"2022-11-02","scope":"insider","n_lines":2},{"id":6378915,"accession":"0001739614-22-000105","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001739614-22-000105","line_url":"/filing/0001739614-22-000105","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Brendan P.; Eckelman Living Trust Dated February 5, 2014","owner_display_name":"Eckelman Brendan P.","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":27.820333335,"price_display":"27.82","price_state":"stated","total_value":1112813.3334,"total_display":"1,112,813.33","total_whole":"1,112,813","shares_owned_after":2256762.0,"shares_owned_after_display":"2,256,762","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-04","filed_date":"2022-10-05","scope":"insider","n_lines":7},{"id":6439880,"accession":"0001739614-22-000095","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001739614-22-000095","line_url":"/filing/0001739614-22-000095","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Living Trust Dated February 5, 2014; Eckelman Brendan P.","owner_display_name":"Eckelman Living Trust Dated February 5, 2014","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":14.9068413025,"price_display":"14.91","price_state":"stated","total_value":596273.6521,"total_display":"596,273.65","total_whole":"596,274","shares_owned_after":2438046.0,"shares_owned_after_display":"2,438,046","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-06","filed_date":"2022-09-07","scope":"insider","n_lines":2},{"id":6614575,"accession":"0001739614-22-000077","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001739614-22-000077","line_url":"/filing/0001739614-22-000077#line-2","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Living Trust Dated February 5, 2014; Eckelman Brendan P.","owner_display_name":"Eckelman Living Trust Dated February 5, 2014","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15500.0,"shares_display":"15,500","price_per_share":18.4651,"price_display":"18.47","price_state":"stated","total_value":286209.05,"total_display":"286,209.05","total_whole":"286,209","shares_owned_after":2475553.0,"shares_owned_after_display":"2,475,553","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-03","filed_date":"2022-08-04","scope":"insider"},{"id":6614574,"accession":"0001739614-22-000077","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001739614-22-000077","line_url":"/filing/0001739614-22-000077#line-1","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Living Trust Dated February 5, 2014; Eckelman Brendan P.","owner_display_name":"Eckelman Living Trust Dated February 5, 2014","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":24500.0,"shares_display":"24,500","price_per_share":17.699,"price_display":"17.70","price_state":"stated","total_value":433625.5,"total_display":"433,625.50","total_whole":"433,626","shares_owned_after":2491053.0,"shares_owned_after_display":"2,491,053","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-02","filed_date":"2022-08-04","scope":"insider"},{"id":6734217,"accession":"0001739614-22-000073","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001739614-22-000073","line_url":"/filing/0001739614-22-000073#line-1","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Living Trust Dated February 5, 2014; Eckelman Brendan P.","owner_display_name":"Eckelman Living Trust Dated February 5, 2014","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":17.17,"price_display":"17.17","price_state":"stated","total_value":686800.0,"total_display":"686,800.00","total_whole":"686,800","shares_owned_after":2515553.0,"shares_owned_after_display":"2,515,553","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-07","filed_date":"2022-07-08","scope":"insider"},{"id":6989375,"accession":"0001739614-22-000039","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001739614-22-000039","line_url":"/filing/0001739614-22-000039#line-1","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Living Trust Dated February 5, 2014; Eckelman Brendan P.","owner_display_name":"Eckelman Living Trust Dated February 5, 2014","owner_url":null,"role":"Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":25.04,"price_display":"25.04","price_state":"stated","total_value":10016.0,"total_display":"10,016.00","total_whole":"10,016","shares_owned_after":2555553.0,"shares_owned_after_display":"2,555,553","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-04-05","filed_date":"2022-04-07","scope":"insider"},{"id":4441090,"accession":"0001739614-21-000051","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001739614-21-000051","line_url":"/filing/0001739614-21-000051#line-1","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Living Trust Dated February 5, 2014; Eckelman Brendan P.","owner_display_name":"Eckelman Living Trust Dated February 5, 2014","owner_url":null,"role":"Director, Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17000.0,"shares_display":"17,000","price_per_share":19.02,"price_display":"19.02","price_state":"stated","total_value":323340.0,"total_display":"323,340.00","total_whole":"323,340","shares_owned_after":2555953.0,"shares_owned_after_display":"2,555,953","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-24","filed_date":"2021-03-24","scope":"insider"},{"id":5308949,"accession":"0001739614-21-000040","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001739614-21-000040","line_url":"/filing/0001739614-21-000040#line-1","is_derivative":false,"issuer_cik":"0001739614","issuer_name":"Inhibrx, Inc.","issuer_ticker":"INBX","issuer_name_source":null,"issuer_url":"/issuer/0001739614","owner_cik":null,"owner_name":"Eckelman Living Trust Dated February 5, 2014; Eckelman Brendan P.","owner_display_name":"Eckelman Living Trust Dated February 5, 2014","owner_url":null,"role":"Director, Officer (Chief Scientific Officer), Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":17000.0,"shares_display":"17,000","price_per_share":25.9,"price_display":"25.90","price_state":"stated","total_value":440300.0,"total_display":"440,300.00","total_whole":"440,300","shares_owned_after":2572953.0,"shares_owned_after_display":"2,572,953","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-16","filed_date":"2021-02-18","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001739614","name":"Inhibrx, Inc.","url":"/issuer/0001739614","role":"Ten percent owner","n_filings":12,"first_seen":"2021-02-18","last_seen":"2023-03-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001821294","retrieved_at":"2026-08-26T11:38:12+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}